Implementation a Data-to-Care Strategy to Improve HIV Continuum Outcomes for Out of Care People Living With HIV (PLWH) in Ukraine
Implementation, Evaluation, and Cost Effectiveness of a Data-to-Care Strategy to Improve HIV Continuum Outcomes for Out of Care PLWH in Ukraine
The goal of this clinical trial is to study the preliminary effectiveness of a data to care intervention versus standard of care for people living with HIV in Ukraine. The main questions it aims to answer are:
- Does a data to care strategy improve primary outcomes of HIV care engagement, antiretroviral therapy initiation or re-initiation, and viral suppression among not-in-care people living with HIV?
- Does a data to care strategy improve secondary outcomes of engagement or re-engagement in ancillary services (e.g., drug treatment) and quality of life?
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: JIll Owczarzak, PhD
- Phone Number: 4105020026
- Email: jillowczarzak@jhu.edu
Study Locations
-
-
-
Kyiv, Ukraine, 21211
- Ukrainian Institute on Public Health Policy
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Registered in the Ukrainian Medical Information System as having received an HIV diagnosis at any time in the past
- missed a clinical visit (medication pick-up or other) more than 7 days ago
- registered with injection drug use (IDU) as probable mode of HIV transmission, or history of IDU documented at any clinical visit
- not been contacted by other clinical staff after the current missed visit
- 18 years or older
Exclusion Criteria:
- Patient is already re-engaged in care and visited the clinic recently
- Patient has sufficient supply of medications (available to him for any reason)
- Patient moved to another clinic, city, country, or penitentiary institution
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Standard of Care
Participants in the standard of care sites will receive existing case management and supportive services from the HIV clinic.
|
Participants can use standard case management and other services offered by the clinic.
|
|
Experimental: Data to Care
Clinics randomized to the intervention arm will implement the data to care strategy, which includes a 5-step process: (1) identify not-in-care PLWH using the a medical information system, (2) verify eligibility criteria, (3) contact patients and invite to visit the clinic, (4) determine care status and reengage into care, and (5) provide case management services and confirm engagement in care.
|
Participants meet with a case manager who asks about health, basic needs such as housing and finances, and relationships and support systems.
A score is assigned that reflects how much support is needed.
A care plan is developed to address areas of need.
The case manager meets regularly with participants to determine if needs are being met and identify strategies for meeting those needs.
Participants with higher scores will receive more intensive contact with case managers, typically every month, until their level of need goes down.
All participants will have their level and types of needs reassessed to determine if they need additional support or are moving toward self-management.
Participants work with case managers for 6 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Engaged in HIV Care as Assessed by Number of Clinical Visits
Time Frame: 12 months
|
At least 3 clinical visits with at least 3 months apart within 12 months after study enrollment
|
12 months
|
|
Number of Participants Initiating ART (re-)Initiation
Time Frame: 3 months
|
Initiating or re-initiating ART within 3 months after study enrollment
|
3 months
|
|
Number of Participants ART Adherent as Assessed by the Percentage of Days in Possession of Medication
Time Frame: One month
|
Number of participants ART adherent assessed by the percentage of days in possession of medication (pharmacy refill gap method)
|
One month
|
|
Number of Participants With HIV Viral Suppression as Assessed by Viral Load (VL) Test
Time Frame: 12 months
|
Having at least one VL test with <200cp/ml and none with >=200cp/ml within 12 months after study enrollment
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Substantial or Severe Substance Use as Assessed by the Drug Abuse Screening Test (DAST-10)
Time Frame: 6 months
|
The Drug Abuse Screening Test (DAST-10) is a 10-item brief screening tool.
Each question requires a yes or no response.
This tool assesses drug use, not including alcohol or tobacco use.
Scores of 0 indicates no problems; 1-2 indicates low level, 3-5 indicates moderate level, 6-8 indicates substantial level, and 9-10 is severe.
|
6 months
|
|
Number of Participants With Moderate or Severe Depressive Symptoms as Assessed by the Patient Health Questionnaire (PHQ-9)
Time Frame: 6 months
|
The Patient Health Questionnaire (PHQ-9) assesses degree of depression severity.
Total scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.
The PHQ-9 scores range from 0-27.
Scores of 10 or higher are indicative of moderate or severe depressive symptoms.
|
6 months
|
|
Health-Related Quality of Life as Assessed by SF12
Time Frame: 6 months
|
General Health Function as measured by the Physical Component of the Medical Outcomes Study SF-12.
The t-scores are based on a standardized reference population with m = 50 and SD = 10.
Higher scores indicate higher functioning.
|
6 months
|
|
HIV-related Risk Behaviors
Time Frame: 6 months
|
HIV transmission risk score based on self-reported episodes of sexual intercourse.
The score is the expected number of onward HIV transmissions over one year (X10000) estimated from Bernoulli transmission models.
Higher scores indicate higher risk of onward HIV transmission.
The index does not have an upper limit.
The Lower limit is 0, and the observed range is 0 - 158.8.
|
6 months
|
|
Trust in Physicians as Assessed by the Trust in Physician Scale (TPS)
Time Frame: One Year
|
Assesses beliefs, opinions, and attitudes about doctors and health issues.
The Trust in Physician Scale is an 11-item self-report instrument developed to assess an individual's trust in his/her physician.
The items use a five point scale (1=Strongly Disagree to 5= Strongly Agree), and the scale has a possible range of 11-55 with higher scores indicating higher trust in physicians.
|
One Year
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Jill Owczarzak, PhD, Johns Hopkins Bloomberg School of Public Health
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Urogenital Diseases
- Genital Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- HIV Infections
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
Other Study ID Numbers
- 00018465
- R34DA053143 (U.S. NIH Grant/Contract)
- IRB00018465 (Other Identifier: JHSPH IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.